SEC Form 4 · accession 0001209191-18-047613
Horizon Pharma plc · HZNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Geoffrey M. Curtis
Officer — EVP, Corporate Affairs, CCO
Period of report
Aug 16, 2018
Accepted (ET)
Aug 20, 2018 · 4:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492426
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Aug 16, 2018 | S | 9,904 | $20.6342 | D | 28,767 | D | |
| Ordinary Shares | holding | — | — | — | 420 | I | By spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.62 to $20.66 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.